Roche's stock demonstrated resilience on the Swiss Stock Exchange SIX, fluctuating between 268.70 CHF and 272.20 CHF with a trading volume exceeding 247,000 shares. Despite a slight dip of 0.61% on October 16, 2024, closing at 268.99 CHF, the pharmaceutical giant maintains a strong market position. The current price sits approximately 7% below its 52-week high of 288.20 CHF and an impressive 21% above its low of 212.90 CHF. Analysts project an average target price of 270.00 CHF, with anticipated earnings per share of 18.55 CHF for 2024. Roche's year-on-year performance shows a notable 5.03% increase, underlining its appeal to long-term investors.
Dividend Outlook Remains Promising
Roche continues to attract income-oriented investors with its robust dividend policy. Experts forecast a dividend of 9.82 CHF for the current year, a slight increase from the previous year's 9.60 CHF. This translates to an projected dividend yield of 4.13%, reflecting the company's solid financial standing and management's confidence in future business development. The pharmaceutical leader is set to release its Q4 2024 financial results on January 30, 2025, an event closely watched by market participants as Roche maintains its significant presence in the Swiss Market Index (SMI).
Ad
Roche Stock: Buy or Sell? New Roche Analysis on 17 October Provides the Answer:The latest Roche figures speak volumes: Urgent action required for Roche shareholders. Is it worth investing, or should you sell? Find out what to do now in our current free analysis from 17 October.
Roche: Buy or Sell? Continue reading here ...